Literature DB >> 15291861

Prevalence of lower urinary tract symptoms in men aged 45-79 years: a population-based study of 40 000 Swedish men.

Swen-Olof Andersson1, Bahram Rashidkhani, Lars Karlberg, Alicja Wolk, Jan-Erik Johansson.   

Abstract

OBJECTIVE: To estimate the age-specific prevalence and severity of lower urinary tract symptoms (LUTS) among Swedish men, the intercorrelations between different symptoms, and to assess quality of life and health-seeking behaviour among men with LUTS. SUBJECTS AND METHODS: In 1997, an International Prostate Symptom Score (IPSS) questionnaire, together with other questions about lifestyle, was mailed to all men aged 45-79 years living in two counties in Sweden; the analyses included 39 928 men.
RESULTS: Overall, 18.5% and 4.8% of the men were moderately and severely symptomatic; the prevalence of at least one symptom was 83%. LUTS were strongly age-dependent, with 1.8% of severe symptoms among men aged 45-49 years and increasing to 9.7% among those 75-79 years old. Frequent urination was the most common symptom among men aged < 70 years and nocturia among those aged >70 years. Symptoms like hesitancy, poor flow and intermittency were highly correlated with each other (Spearman coefficients 0.56-0.60). There was a high correlation between the IPSS and a poor score for quality of life resulting from the bothersomeness of LUTS (r = 0.70). Among symptomatic subjects, 36% reported a poor quality of life (fairly bad, very bad or terrible). Only 29% of symptomatic subjects (IPSS >7) reported that they had been diagnosed previously for their urinary problems, and only 11% received medication for that.
CONCLUSION: Although the prevalence of LUTS in Sweden is high, the percentage of men whose quality of life is substantially affected is much lower.

Entities:  

Mesh:

Year:  2004        PMID: 15291861     DOI: 10.1111/j.1464-410X.2004.04930.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  29 in total

1.  Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men.

Authors:  Sean A Martin; Matthew T Haren; Villis R Marshall; Kylie Lange; Gary A Wittert
Journal:  World J Urol       Date:  2010-10-21       Impact factor: 4.226

2.  Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients.

Authors:  Tong Zhang; Haihu Wu; Shuai Liu; Wei He; Kejia Ding
Journal:  Int Urol Nephrol       Date:  2017-04-13       Impact factor: 2.370

3.  Lower Urinary Tract Symptoms and Risk of Bladder Cancer in Men: Results From the Health Professionals Follow-up Study.

Authors:  Jiachen Zhou; Karl T Kelsey; Scott Smith; Edward Giovannucci; Dominique S Michaud
Journal:  Urology       Date:  2015-04-08       Impact factor: 2.649

4.  Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.

Authors:  Julia H Hayes; Daniel A Ollendorf; Steven D Pearson; Michael J Barry; Philip W Kantoff; Susan T Stewart; Vibha Bhatnagar; Christopher J Sweeney; James E Stahl; Pamela M McMahon
Journal:  JAMA       Date:  2010-12-01       Impact factor: 56.272

5.  Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis.

Authors:  David Liu; Harold P Lehmann; Kevin D Frick; H Ballentine Carter
Journal:  J Urol       Date:  2012-02-14       Impact factor: 7.450

Review 6.  The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.

Authors:  Júlio Fonseca; Carlos Martins da Silva
Journal:  Clin Drug Investig       Date:  2015-02       Impact factor: 2.859

7.  Triptorelin for the relief of lower urinary tract symptoms in men with advanced prostate cancer: results of a prospective, observational, grouped-analysis study.

Authors:  Thierry Gil; Fouad Aoun; Patrick Cabri; Valérie Perrot; Roland van Velthoven
Journal:  Ther Adv Urol       Date:  2017-06-21

8.  Energy delivery systems for treatment of benign prostatic hyperplasia: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-08-01

9.  Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.

Authors:  Julia H Hayes; Daniel A Ollendorf; Steven D Pearson; Michael J Barry; Philip W Kantoff; Pablo A Lee; Pamela M McMahon
Journal:  Ann Intern Med       Date:  2013-06-18       Impact factor: 25.391

10.  Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study.

Authors:  Young-Suk Lee; Kyu-Sung Lee; Jae Hun Jung; Deok Hyun Han; Seung-June Oh; Ju Tae Seo; Jeong Gu Lee; Hye Sook Park; Myung-Soo Choo
Journal:  World J Urol       Date:  2009-11-08       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.